Denali Therapeutics Inc [DNLI] stock is trading at $23.35, up 38.25%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DNLI shares have gain 41.17% over the last week, with a monthly amount glided 38.41%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights. In a post published today on Yahoo Finance, Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on December 13, 2023, when Citigroup initiated its Buy rating and assigned the stock a price target of $32. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $38 on September 06, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $50 as its price target on January 30, 2023. In a note dated November 02, 2022, BTIG Research upgraded an Buy rating on this stock but restated the target price of $38.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $15.45 and $33.31 over the past year. Currently, Wall Street analysts expect the stock to reach $91 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $23.35 at the most recent close of the market. An investor can expect a potential return of 289.72% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Denali Therapeutics Inc [NASDAQ:DNLI] reported sales of 330.53M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.17 points at the first support level, and at 16.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.02, and for the 2nd resistance point, it is at 26.70.
Denali Therapeutics Inc [DNLI] reported earnings per share of -$0.72 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.8/share, meaning a difference of $0.08 and a surprise factor of 10.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $1.3 per share as compared to estimates of -$0.68 per share, a difference of $1.98 representing a surprise of 291.20%.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 13.65. In addition, the Quick Ratio stands at 16.06 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 9.76, the price to book ratio is 2.88.
Transactions by insiders
Recent insider trading involved SATO VICKI L, Director, that happened on Feb 15 when 1666.0 shares were sold. COFO and Secretary, Schuth Alexander O. completed a deal on Feb 14 to sell 20128.0 shares. Meanwhile, Chief Medical Officer Ho Carole sold 1405.0 shares on Feb 14.
